Literature DB >> 22659092

Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10.

Barbara Fedejko-Kap1, Stacie M Bratton, Moshe Finel, Anna Radominska-Pandya, Zofia Mazerska.   

Abstract

5-Diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311 (NSC-645809), is an antitumor agent shown to be effective against breast cancer in phase II clinical trials. A similar compound, 5-dimethylaminopropylamino-8-hydroxytriazoloacridinone, C-1305, shows high activity against experimental tumors and is expected to have even more beneficial pharmacological properties than C-1311. Previously published studies showed that these compounds are not substrates for cytochrome P450s; however, they do contain functional groups that are common targets for glucuronidation. Therefore, the aim of this work was to identify the human UDP-glucuronosyltransferases (UGTs) able to glucuronidate these two compounds. High-performance liquid chromatography analysis was used to examine the activities of human recombinant UGT1A and UGT2B isoforms and microsomes from human liver [human liver microsomes (HLM)], whole human intestinal mucosa [human intestinal microsomes (HIM)], and seven isolated segments of human gastrointestinal tract. Recombinant extrahepatic UGT1A10 glucuronidated 8-hydroxyl groups with the highest catalytic efficiency compared with other recombinant UGTs, V(max)/K(m) = 27.2 and 8.8 μl · min⁻¹ · mg protein⁻¹, for C-1305 and C-1311, respectively. In human hepatic and intestinal microsomes (HLM and HIM, respectively), high variability in UGT activities was observed among donors and for different regions of intestinal tract. However, both compounds underwent UGT-mediated metabolism to 8-O-glucuronides by microsomes from both sources with comparable efficiency; V(max)/K(m) values were from 4.0 to 5.5 μl · min⁻¹ · mg protein⁻¹. In summary, these studies suggest that imid azoacridinone and triazoloacridinone drugs are glucuronidated in human liver and intestine in vivo and may form the basis for future translational studies of the potential role of UGTs in resistance to these drugs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659092      PMCID: PMC3422538          DOI: 10.1124/dmd.112.045401

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  44 in total

Review 1.  Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions.

Authors:  J K Ritter
Journal:  Chem Biol Interact       Date:  2000-12-01       Impact factor: 5.192

2.  Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry.

Authors:  David E Harbourt; John K Fallon; Shinya Ito; Takashi Baba; Joseph K Ritter; Gary L Glish; Philip C Smith
Journal:  Anal Chem       Date:  2011-12-05       Impact factor: 6.986

3.  Enzymatic activation of a new antitumour drug, 5-diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNA.

Authors:  Z Mazerska; J Dziegielewski; J Konopa
Journal:  Biochem Pharmacol       Date:  2001-03-15       Impact factor: 5.858

4.  Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells.

Authors:  Barbara Fedejko-Kap; Magdalena Niemira; Anna Radominska-Pandya; Zofia Mazerska
Journal:  Xenobiotica       Date:  2011-08-23       Impact factor: 1.908

5.  Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine.

Authors:  P Klepstad; S Kaasa; P C Borchgrevink
Journal:  Eur J Clin Pharmacol       Date:  2000-01       Impact factor: 2.953

6.  Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents.

Authors:  Steven C Smith; Dmytro M Havaleshko; Kihyuck Moon; Alexander S Baras; Jae Lee; Stefan Bekiranov; Daniel J Burke; Dan Theodorescu
Journal:  Neoplasia       Date:  2011-01       Impact factor: 5.715

7.  UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate.

Authors:  M Cristina de Almagro; Elisabet Selga; Rémi Thibaut; Cinta Porte; Véronique Noé; Carlos J Ciudad
Journal:  Biochem Pharmacol       Date:  2010-09-18       Impact factor: 5.858

8.  Phenylalanine 93 of the human UGT1A10 plays a major role in the interactions of the enzyme with estrogens.

Authors:  Camilla Höglund; Nina Sneitz; Anna Radominska-Pandya; Liisa Laakonen; Moshe Finel
Journal:  Steroids       Date:  2011-08-09       Impact factor: 2.668

Review 9.  The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance.

Authors:  A Starlard-Davenport; B Lyn-Cook; F A Beland; I P Pogribny
Journal:  Exp Oncol       Date:  2010-09

10.  The imidazoacridinone antitumor drug, C-1311, is metabolized by flavin monooxygenases but not by cytochrome P450s.

Authors:  Agnieszka Potega; Emilia Dabrowska; Magdalena Niemira; Agata Kot-Wasik; Sebastien Ronseaux; Colin J Henderson; C Roland Wolf; Zofia Mazerska
Journal:  Drug Metab Dispos       Date:  2011-05-09       Impact factor: 3.922

View more
  4 in total

1.  The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.

Authors:  Ewa Augustin; Anna Skwarska; Anna Weryszko; Iwona Pelikant; Ewa Sankowska; Barbara Borowa-Mazgaj
Journal:  Acta Pharmacol Sin       Date:  2015-02-02       Impact factor: 6.150

2.  Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use.

Authors:  Monika Pawlowska; Rong Chu; Barbara Fedejko-Kap; Ewa Augustin; Zofia Mazerska; Anna Radominska-Pandya; Timothy C Chambers
Journal:  Drug Metab Dispos       Date:  2012-11-16       Impact factor: 3.922

3.  CYP3A4 overexpression enhances apoptosis induced by anticancer agent imidazoacridinone C-1311, but does not change the metabolism of C-1311 in CHO cells.

Authors:  Monika Pawłowska; Ewa Augustin; Zofia Mazerska
Journal:  Acta Pharmacol Sin       Date:  2013-12-02       Impact factor: 6.150

4.  Enhanced Activity of P4503A4 and UGT1A10 Induced by Acridinone Derivatives C-1305 and C-1311 in MCF-7 and HCT116 Cancer Cells: Consequences for the Drugs' Cytotoxicity, Metabolism and Cellular Response.

Authors:  Monika Pawłowska; Anna Kwaśniewska; Zofia Mazerska; Ewa Augustin
Journal:  Int J Mol Sci       Date:  2020-05-31       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.